Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide or zanubrutinib plus prednisone, etoposide, and lenalidomide induction followed by CD20 antibody and bendamustine consolidation in relapsed or refractory indolent B-cell non-Hodgkin lymphoma
ChiCTR2100047272Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, zanubrutinib, prednisone, etoposide, lenalidomide and 2 more in mature B-cell lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
tucidinostatzanubrutinibprednisoneetoposidelenalidomide
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2100047272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047272.